111 Capital Sells 1,403 Shares of Eli Lilly and Company $LLY

111 Capital decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 48.0% in the 2nd quarter, Holdings Channel reports. The fund owned 1,518 shares of the company’s stock after selling 1,403 shares during the period. 111 Capital’s holdings in Eli Lilly and Company were worth $1,183,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares in the last quarter. Matrix Trust Co increased its holdings in shares of Eli Lilly and Company by 25.9% during the first quarter. Matrix Trust Co now owns 267 shares of the company’s stock worth $221,000 after buying an additional 55 shares in the last quarter. Beacon Financial Group increased its holdings in Eli Lilly and Company by 4.2% in the 1st quarter. Beacon Financial Group now owns 446 shares of the company’s stock worth $368,000 after purchasing an additional 18 shares in the last quarter. Finally, Charles Schwab Trust Co increased its holdings in Eli Lilly and Company by 41.1% in the 1st quarter. Charles Schwab Trust Co now owns 453 shares of the company’s stock worth $374,000 after purchasing an additional 132 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. HSBC raised Eli Lilly and Company from a “reduce” rating to a “hold” rating and upped their price objective for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Cantor Fitzgerald decreased their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $933.39.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $840.46 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The firm’s fifty day simple moving average is $734.60 and its two-hundred day simple moving average is $766.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 EPS. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In related news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.